Biohaven underscores depth of migraine portfolio with data from nurtec® odt (rimegepant) long-term open label study and phase 3 zavegepant trial at 64th annual scientific meeting of the american headache society

31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust nurtec odt, zavegepant and migraine heor data late-breaking submissions showcase new data for nurtec odt in chinese and korean patients and patterns of medication utilization in adults using it as an acute and preventive treatment results from long-term studies of nurtec odt as a preventive and acute treatment of migraine showed more than 80% of patients achieved ≥50% reduction in moderate or severe monthly migraine days and approximately half experienced a 100% reduction other oral presentations included safety and efficacy of zavegepant nasal spray as an acute treatment of migraine and an analysis of placebo responses over time in oral migraine preventive trials new haven, conn. , june 9, 2022 /prnewswire/ -- biohaven pharmaceutical holding company ltd.
BHVN Ratings Summary
BHVN Quant Ranking